Table 1 Patient descriptive characteristics
Characteristic | Overall | Black | White | p-value |
|---|---|---|---|---|
Total | 611 | 507 (83.0) | 104 (17.0) | |
Age at diagnosis, Mean (SD) | 53.6 (11.0) | 53.8 (11.1) | 52.5 (10.6) | 0.25 |
BMI (kg/m2), Median (IQR) | 29.9 (26.2–34.7) | 30.5 (26.8–35.6) | 26.6 (22.8–30.9) | < 0.001 |
ER status | 0.01 | |||
ER+ | 419 (68.6) | 337 (66.5) | 82 (78.8) | |
ER- | 192 (31.4) | 170 (33.5) | 22 (21.2) | |
Subtype | 0.04 | |||
Luminal | 359 (59.2) | 293 (58.4) | 66 (63.5) | |
HER2+ | 104 (17.2) | 81 (16.1) | 23 (22.1) | |
Triple negative | 143 (23.6) | 128 (25.5) | 15 (14.4) | |
Stage | 0.96 | |||
I | 260 (42.6) | 217 (42.8) | 43 (41.3) | |
II | 269 (44.0) | 222 (43.8) | 47 (45.2) | |
III/IV | 82 (13.4) | 68 (13.4) | 14 (13.5) | |
Grade | 0.003 | |||
1 | 82 (13.6) | 63 (12.6) | 19 (18.8) | |
2 | 213 (35.4) | 167 (33.3) | 46 (45.5) | |
3 | 307 (51.0) | 271 (54.1) | 36 (35.6) | |
Tumor size (cm), Median (IQR) | 2.0 (1.3–2.8) | 2.0 (1.3–3.0) | 1.9 (1.2–2.5) | 0.28 |
Node status | 0.45 | |||
Positive | 242 (40.4) | 197 (39.7) | 45 (43.7) | |
Negative | 357 (59.6) | 299 (60.3) | 58 (56.3) | |
Surgery | 0.71 | |||
No | 13 (2.2) | 12 (2.4) | 1 (1.0) | |
Yes | 591 (97.8) | 489 (97.6) | 102 (99.0) | |
Chemotherapy | 0.35 | |||
No | 200 (33.1) | 170 (33.9) | 30 (29.1) | |
Yes | 404 (66.9) | 331 (66.1) | 73 (70.9) | |
Radiation | < 0.001 | |||
No | 212 (35.2) | 158 (31.5) | 54 (53.5) | |
Yes | 390 (64.8) | 343 (68.5) | 47 (46.5) | |
Hormone therapy | 0.75 | |||
No | 226 (37.5) | 186 (37.2) | 40 (38.8) | |
Yes | 377 (62.5) | 314 (62.8) | 63 (61.2) | |
Vital status | ||||
Alive | 419 (76.7) | 361 (77.5) | 58 (72.5) | |
Breast cancer-specific death | 66 (12.1) | 54 (11.6) | 12 (15.0) | |
Non-breast cancer-specific death | 61 (11.2) | 51 (10.9) | 10 (12.5) | |
Follow-up time (years), median (IQR) | 9.7 (7.4–12.3) | 9.3 (7.2–11.0) | 15.1 (13.4–16.1) |